A phase I study of GC33 in Japanese patients with advanced hepatocellular carcinoma (HCC).
Takuji Okusaka
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Masafumi Ikeda
Stock Ownership - Bayer; Chugai Pharma; Novartis
Honoraria - Bayer; Chugai Pharma; Novartis
Research Funding - Bayer; Chugai Pharma; Novartis
Shinichi Ohkawa
Stock Ownership - Chugai Pharma; Lilly; Taiho Pharmaceutical
Honoraria - Chugai Pharma; Lilly; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Lilly; OncoTherapy Science; Taiho Pharmaceutical; Takeda
Shunsuke Yamamoto
No relevant relationships to disclose
Ikue Suzuki
No relevant relationships to disclose
Junji Furuse
Honoraria - Bayer; Chugai Pharma; Eisai; Lilly; Taiho Pharmaceutical
Research Funding - Bayer; Chugai Pharma; GlaxoSmithKline; Lilly; Taiho Pharmaceutical; Takeda
Expert Testimony - Bayer; Chugai Pharma; Eisai; GlaxoSmithKline; Lilly; Taiho Pharmaceutical